HK1253238A1 - 用於治療疾病的gls1抑制劑 - Google Patents
用於治療疾病的gls1抑制劑Info
- Publication number
- HK1253238A1 HK1253238A1 HK18112524.0A HK18112524A HK1253238A1 HK 1253238 A1 HK1253238 A1 HK 1253238A1 HK 18112524 A HK18112524 A HK 18112524A HK 1253238 A1 HK1253238 A1 HK 1253238A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating disease
- gls1 inhibitors
- gls1
- inhibitors
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187160P | 2015-06-30 | 2015-06-30 | |
| US201562270355P | 2015-12-21 | 2015-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1253238A1 true HK1253238A1 (zh) | 2019-06-14 |
Family
ID=57609112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112524.0A HK1253238A1 (zh) | 2015-06-30 | 2018-09-28 | 用於治療疾病的gls1抑制劑 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10125128B2 (zh) |
| EP (1) | EP3316887B1 (zh) |
| JP (1) | JP6895396B2 (zh) |
| CN (1) | CN107921044B (zh) |
| AU (1) | AU2016287661B2 (zh) |
| CA (1) | CA2990457A1 (zh) |
| ES (1) | ES2794868T3 (zh) |
| HK (1) | HK1253238A1 (zh) |
| WO (1) | WO2017004359A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074805B (zh) | 2014-07-03 | 2021-02-26 | 德州大学***董事会 | 用于治疗疾病的gls1抑制剂 |
| CA2990457A1 (en) | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Pyrrolidinyl and piperidinyl derivatives and pharmaceutical compositions thereof useful as gls1 inhibitors |
| US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
| WO2018228435A1 (zh) * | 2017-06-13 | 2018-12-20 | 南京明德新药研发股份有限公司 | 作为gls1抑制剂的化合物 |
| RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
| AU2019363115B2 (en) * | 2018-10-16 | 2021-12-09 | Medshine Discovery Inc. | Thiadiazole derivative and uses thereof as a GLS1 inhibitor |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN111440199B (zh) * | 2020-03-11 | 2023-02-24 | 中国药科大学 | 大环类谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
| CN114560855B (zh) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 环烷基甲酰胺类衍生物、其制备方法及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES498337A0 (es) | 1980-01-07 | 1982-06-01 | Nyegaard & Co As | Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas |
| DE3572230D1 (en) | 1985-10-10 | 1989-09-14 | Agfa Gevaert Nv | Image-recieving element for the silver salt diffusion transfer reversal process |
| AU6979091A (en) | 1989-12-22 | 1991-07-24 | Upjohn Company, The | Pyridinones useful as antiatherosclerotic agents |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| AU725035B2 (en) | 1995-07-21 | 2000-10-05 | Constantia Gruppe | Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| WO1999026945A1 (en) | 1997-11-26 | 1999-06-03 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2008124660A2 (en) | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| PT2247592E (pt) | 2008-02-25 | 2011-11-03 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
| SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| SG10201400235PA (en) | 2009-02-27 | 2014-07-30 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
| JP5725475B2 (ja) | 2010-01-21 | 2015-05-27 | 公立大学法人名古屋市立大学 | ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤 |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| EA026656B1 (ru) * | 2011-11-21 | 2017-05-31 | Калитера Байосайенсиз Инк. | Гетероциклические ингибиторы глютаминазы |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| MX2015005963A (es) | 2012-11-16 | 2015-09-16 | Calithera Biosciences Inc | Inhibidores heterociclicos de glutaminasa. |
| BR112015011756A2 (pt) | 2012-11-21 | 2017-07-11 | Agios Pharmaceuticals Inc | inibidores da glutamase e métodos de uso |
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| SG11201504184PA (en) * | 2012-12-03 | 2015-06-29 | Calithera Biosciences Inc | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| BR112015016310B1 (pt) | 2013-01-30 | 2020-12-22 | Sumitomo Chemical Company, Limited | composto de amida, agente de controle e método para controlar peste artrópode |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| KR20220013017A (ko) * | 2014-01-06 | 2022-02-04 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| US20160002248A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
| WO2016004418A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| US20160058759A1 (en) | 2014-07-03 | 2016-03-03 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| CN107074805B (zh) | 2014-07-03 | 2021-02-26 | 德州大学***董事会 | 用于治疗疾病的gls1抑制剂 |
| US20160002204A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
| CA2990457A1 (en) | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Pyrrolidinyl and piperidinyl derivatives and pharmaceutical compositions thereof useful as gls1 inhibitors |
| US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
| RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
-
2016
- 2016-06-30 CA CA2990457A patent/CA2990457A1/en active Pending
- 2016-06-30 AU AU2016287661A patent/AU2016287661B2/en active Active
- 2016-06-30 CN CN201680042926.4A patent/CN107921044B/zh active Active
- 2016-06-30 WO PCT/US2016/040364 patent/WO2017004359A1/en active Application Filing
- 2016-06-30 JP JP2017568456A patent/JP6895396B2/ja active Active
- 2016-06-30 EP EP16818780.5A patent/EP3316887B1/en active Active
- 2016-06-30 ES ES16818780T patent/ES2794868T3/es active Active
- 2016-06-30 US US15/199,100 patent/US10125128B2/en active Active
-
2018
- 2018-09-28 HK HK18112524.0A patent/HK1253238A1/zh unknown
- 2018-10-05 US US16/152,901 patent/US10738043B2/en active Active
-
2020
- 2020-07-01 US US16/918,897 patent/US11713313B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018520158A (ja) | 2018-07-26 |
| CN107921044B (zh) | 2022-01-21 |
| US10738043B2 (en) | 2020-08-11 |
| CA2990457A1 (en) | 2017-01-05 |
| US10125128B2 (en) | 2018-11-13 |
| EP3316887A4 (en) | 2019-01-16 |
| JP6895396B2 (ja) | 2021-06-30 |
| US20170001996A1 (en) | 2017-01-05 |
| CN107921044A (zh) | 2018-04-17 |
| AU2016287661A1 (en) | 2018-01-04 |
| EP3316887B1 (en) | 2020-04-08 |
| US20190031651A1 (en) | 2019-01-31 |
| WO2017004359A1 (en) | 2017-01-05 |
| ES2794868T3 (es) | 2020-11-19 |
| BR112017028309A2 (pt) | 2018-09-04 |
| US20210122744A1 (en) | 2021-04-29 |
| US11713313B2 (en) | 2023-08-01 |
| EP3316887A1 (en) | 2018-05-09 |
| AU2016287661B2 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251407A1 (zh) | 治療癌症的方法 | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| ZA201705673B (en) | Methods for treating skin | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| HK1249469A1 (zh) | 用RORγ抑制劑治療癌症的方法 | |
| IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
| HK1253238A1 (zh) | 用於治療疾病的gls1抑制劑 | |
| HK1244217A1 (zh) | 用於治療蛋白質病的方法 | |
| PT3164394T (pt) | Inibidores gls1 para o tratamento de doenças | |
| PT3393468T (pt) | Métodos para tratar imunodeficiências | |
| HK1250944A1 (zh) | 用於治療癌症的方法 | |
| HK1255871A1 (zh) | 用於治療骨髓瘤的賽度替尼 | |
| HK1250942A1 (zh) | 用於治療癌症的方法 | |
| HK1248133A1 (zh) | 治療神經母細胞瘤的方法 | |
| GB201501004D0 (en) | Inhibitors | |
| HK1250943A1 (zh) | 用於治療癌症的方法 | |
| PT3250218T (pt) | Péptido natkide para o tratamento da obesidade | |
| IL249616A0 (en) | Methods for treating inflammation | |
| GB201520949D0 (en) | Inhibitors |